Figure 6. CGI hypomethylation associated with cell of origin and elevated H3K4me3 provides a potential therapeutic vulnerability.

(a) Fractional methylation of SyS and a collection of IHEC tissues in CGI shores. (b) Fractional methylation of genome wide, promoters, CGIs and CGI shores in the hSS2, Ctrl and E12.5 mouse samples. (c) Cell viability assay in SyS (HYSSII and SYO1) and Osteosarcoma (U2OS) cells upon 7-day treatment with the WDR5 inhibitor OICR-9429. (d) Cell competition assay performed in the SyS lines (HSSYII, SYO1, and Yamato) and Osteosarcoma (KHOS) cells transduced with an empty sgRNA as control or with guides targeting WDR5. (e) Proposed summative model. * indicates P-value < 0.05 using pairwise Wilcoxon signed-rank test.